

Press release Banque Delubac & Cie - Corporate & Investment Bank – December 07<sup>th</sup> 2020

## **Voluntis successfully completes a capital increase of 5.9 million euros and finalises the financing of its strategic development plan.**

**Banque Delubac & Cie supports Voluntis in carrying out a capital increase by private placement to the value of € 5.9 million.**



Voluntis, a company listed on Euronext Paris and **leader in the field of digital therapeutics**, has completed a capital increase by private placement without preferential subscription rights for a total amount of **5.9 million euros**.

The securities were subscribed by quality European investors, mostly specialised in the health sector, including **Debiopharm Innovation Fund**, corporate fund of the Swiss company Debiopharm and **Indigo**, personal holding company of Eric Carreel, Chairman and co-founder of Withings, which has strengthened its position. The issue price of the new shares was set at **€ 4.43 per share**, i.e. a discount of 15% compared to the average price weighted volume of the last 3 trading sessions preceding its setting.

The objective of this transaction is to **strengthen Voluntis' financial resources**, in particular to **develop its commercial activities with the pharmaceutical industry** and to contribute to the **financing of R&D activities**. This fundraising complements the financing tools already in place, in particular the State guaranteed loan (PGE) of 2 million euros and the recently obtained R&D Innovation loan of 1 million euros and allows the company to cover its financing needs beyond the next 12 months.

*"First of all, I would like to thank the investors who placed their trust in us and contributed to the success of this transaction. We were committed to equip ourselves, as quickly as possible, with the financial visibility necessary to execute our strategic roadmap. We can now focus on completing the developments for the marketing of digital therapeutics within the framework of the agreements already concluded and on the negotiation of new collaborations with pharmaceutical companies"* explains Pierre Leurent, Voluntis CEO.

*“We were very pleased to advise Voluntis in this capital structuring transaction, which will enable it to strengthen its financial resources including its R & D and continue to roll out its strategic plan with pharmaceutical industry leaders”* explains Christine Lambert-Goué, Corporate & Investment Bank Director at Banque Delubac & Cie.

**The offering was led by Bank Delubac & Cie - CIB as leader, adviser and global coordinator of the transaction.**

#### **About Voluntis**

Voluntis develops digital therapeutics to help patients with chronic diseases better manage their daily treatment and improve its effectiveness. Using both mobile and web applications, Voluntis solutions use medical algorithms to instantly provide customised recommendations to the patient and their healthcare team. These recommendations may, for example, be to adjust the dosage of a treatment to manage side effects or symptom monitoring, while allowing remote patient monitoring. Using its Theraxium platform, Voluntis has developed multiple digital therapeutics, particularly in oncology and diabetes. Voluntis has established long-term partnerships with leading companies in the field of life sciences. Based in Cambridge, MA, and Paris, France, Voluntis is a founding member of the Digital Therapeutics Alliance.

For more information: <https://www.voluntis.com/>

#### **About Banque Delubac & Cie**

Banque Delubac & Cie, founded in 1924, is an independent financial institution offering banking and specialised financial services. Employing more than 200 employees, it has branches in Paris, Lyon, Toulouse, Valencia and Le Cheylard (historic headquarters located in the Ardèche).

Over the last 10 years, its Corporate & Investment Bank department has developed an advisory service in mergers and acquisitions, financial engineering and transactions for listed and unlisted companies.

More information: <https://www.delubac.com/>

#### **Transaction advisers:**

##### **Leader and transaction adviser**

*Banque Delubac & Cie*

Mickaël Hazout – CIB Managing Director - [mickael.hazout@delubac.fr](mailto:mickael.hazout@delubac.fr)

Christine Lambert-Goué – CIB Director - [christine.lambertgoue@delubac.fr](mailto:christine.lambertgoue@delubac.fr)

##### **Press contact: Langage et Projets Conseils : 01 53 26 42 10**

*Laurent Payet – [laurent@lp-conseils.com](mailto:laurent@lp-conseils.com) – 06 89 95 48 87*

*Patricia Ide Beretti – [patricia@lp-conseils.com](mailto:patricia@lp-conseils.com) – 07 79 82 30 75*